Trump announces trade deal with EU following months of negotiations
Birgit Girshick, Corporate Executive Vice President and Chief Operating Officer at Charles River Laboratories International, Inc. (NYSE:CRL), has made a notable acquisition of company stock. According to a recent SEC filing, Girshick purchased 1,514 shares of common stock on February 20, 2025. The shares were bought at a price of $164.63 each, amounting to a total transaction value of approximately $249,249. The purchase price sits near the lower end of CRL’s 52-week range of $150.79 to $275.00, with InvestingPro analysis indicating the stock is currently undervalued. Following this transaction, Girshick now owns 55,058 shares directly. This move reflects a significant investment in the company by a top executive, underscoring confidence in Charles River Laboratories’ future prospects. The insider purchase aligns with broader management actions, as InvestingPro data shows management has been actively buying back shares. With a market capitalization of $8.3 billion and expected net income growth this year, investors can access detailed insider trading patterns and 12+ additional ProTips through the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Charles River Laboratories International, Inc. reported its fourth-quarter 2024 earnings, which exceeded analyst expectations. The company achieved an earnings per share (EPS) of $2.66, surpassing the forecasted $2.54, and generated revenue of $1 billion, exceeding the anticipated $985.18 million. Despite these positive results, Evercore ISI revised its price target for Charles River Labs to $175 from $195, maintaining an "In Line" rating, citing realistic expectations for 2025 amidst demand constraints.
Additionally, company executives, including CEO James C. Foster, made notable stock purchases, with Foster acquiring 6,075 shares. These transactions followed the termination of their Rule 10b5-1 Trading Plans. The company’s strategic initiatives, such as operational restructuring, are projected to save $225 million annually by 2026, although the 2025 guidance suggests a 3.5% to 5.5% organic revenue decline.
Charles River Labs’ management has also outlined plans to repurchase $350 million in stock to bolster shareholder value. Meanwhile, the company is addressing longer-term structural changes, including cost-cutting initiatives and share repurchase strategies, as noted by Evercore ISI. These developments reflect the company’s efforts to navigate current market challenges and align with industry trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.